Catalyst Biosciences Announces Presentation at the 60th American Society of Hematology Annual Meeting & Exposition
November 02 2018 - 8:00AM
Catalyst Biosciences, Inc. (NASDAQ: CBIO), a clinical-stage
biopharmaceutical company focused on developing novel medicines to
address hematology indications, today announced that
Dr. Howard Levy, chief medical officer of Catalyst, will
deliver a poster presentation at the 60th American Society of
Hematology (ASH) Annual Meeting & Exposition being held
in San Diego from December 1-4, 2018. The
marzeptacog alfa (activated) MAA-201 trial results that will be
presented at the meeting will include pharmacokinetic, efficacy and
safety data from additional enrolled subjects not available at the
time the abstract was submitted to the Congress.
Poster presentation
details |
|
Presentation
Title: |
|
Phase 2/3 Trial of Subcutaneously Administered Marzeptacog
Alfa (activated) an Engineered FVIIa in Hemophilia with Inhibitors
- Pharmacokinetics, Pharmacodynamics, Safety and
Efficacy |
|
Presenter: |
|
Howard Levy, M.B.B.Ch.,
Ph.D., M.M.M. |
|
Session: |
|
322. Disorders of
Coagulation or Fibrinolysis: Poster I |
|
Date/Time: |
|
Saturday, Dec. 1, 2018
from 6:15 - 8:15 p.m. PST |
A copy of the presentation materials can be accessed on
the Events and Presentations section of the Catalyst
website once the presentation concludes.
About Catalyst Biosciences Catalyst is a
clinical-stage biopharmaceutical company developing novel medicines
to address hematology indications. Catalyst is focused on the field
of hemostasis, including the subcutaneous prophylaxis of hemophilia
and facilitating surgery in individuals with hemophilia. For more
information, please visit www.catalystbiosciences.com.
Forward-Looking StatementsThis press release
contains forward-looking statements about the potential uses and
benefits of Catalyst’s product candidates. These
forward-looking statements involve substantial risks and
uncertainties. Actual results or events could differ materially
from the plans, intentions, expectations and projections disclosed
in the forward-looking statements. Various important factors could
cause actual results or events to differ materially from the
forward-looking statements that the Company makes, including, but
not limited to, the risk that trials and studies may be delayed and
may not have satisfactory outcomes, that human trials will not
replicate the results from animal studies, that potential adverse
effects may arise from the testing or use of the Company’s
products, including the generation of antibodies, the risk that
costs required to develop or manufacture the Company’s products
will be higher than anticipated, competition and other factors that
affect our ability to establish collaborations on commercially
reasonable terms and other risks described in the “Risk Factors”
section of the Company’s Quarterly Report on Form 10-Q for the
quarter ended September 30, 2018, filed with
the Securities and Exchange Commission on November
1, 2018, along with other filings with the Securities and
Exchange Commission. The Company does not assume any obligation to
update any forward-looking statements, except as required by
law.
ContactsInvestors: Fletcher
Payne, CFO Catalyst Biosciences, Inc. +1.650.871.0761
investors@catbio.com
Media: Josephine Belluardo, Ph.D. LifeSci
Public Relations +1.646.751.4361 jo@lifescipublicrelations.com
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Catalyst Biosciences (NASDAQ:CBIO)
Historical Stock Chart
From Apr 2023 to Apr 2024